MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Atlantic Boulevard, Fajara, PO Box 273, Banjul, The Gambia.
Division of Women and Children's Health, King's College London, St Thomas' Hospital, 10th Floor North Wing, London, SE1 7EH, UK.
BMC Med. 2019 Feb 18;17(1):38. doi: 10.1186/s12916-019-1264-2.
Thymic size in early infancy predicts subsequent survival in low-income settings. The human thymus develops from early gestation, is most active in early life and is highly sensitive to malnutrition. Our objective was to test whether thymic size in infancy could be increased by maternal and/or infant nutritional supplementation.
The Early Nutrition and Immune Development (ENID) Trial was a randomized 2 × 2 × 2 factorial, partially blinded trial of nutritional supplementation conducted in rural Gambia, West Africa. Pregnant women (N = 875) were randomized to four intervention groups (iron-folate (standard care), multiple micronutrients, protein energy or protein energy + multiple micronutrients at 'booking' (mean gestational age at enrolment = 13.6 weeks, range 8-20 weeks) until delivery. The iron-folate and multiple micronutrient arms were administered in tablet form and the protein energy arms as a lipid-based nutritional supplement. All intervention arms contained 60 mg iron and 400 μg folic acid per daily dose. From 24 to 52 weeks of age, infants from all groups were randomized to receive a daily lipid-based nutritional supplement, with or without additional micronutrients. Thymic size was assessed by ultrasonography at 1, 8, 24 and 52 weeks of infant age, and a volume-related thymic index calculated. Detailed data on infant growth, feeding status and morbidity were collected.
A total of 724 (82.7%) mother-infant pairs completed the trial to infant age 52 weeks. Thymic size in infancy was not significantly associated with maternal supplement group at any post-natal time point. Infants who received the daily LNS with additional micronutrients had a significantly larger thymic index at 52 weeks of age (equivalent to an 8.0% increase in thymic index [95% CI 2.89, 13.4], P = 0.002). No interaction was observed between maternal and infant supplement groups.
A micronutrient-fortified lipid-based supplement given in the latter half of infancy increased thymic size, a key mediator of immune function. Improving the micronutrient status of infants from populations with marginal micronutrient status may improve immune development and survival.
ISRCTN registry (controlled-trials.com) Identifier: ISRCTN49285450.
婴儿期的胸腺大小可预测低收入环境中的后续生存情况。人类胸腺从早期妊娠开始发育,在生命早期最为活跃,对营养不良高度敏感。我们的目的是测试婴儿期的胸腺大小是否可以通过母亲和/或婴儿营养补充来增加。
早期营养与免疫发育(ENID)试验是一项在西非冈比亚农村地区进行的随机 2×2×2 析因、部分盲法营养补充试验。孕妇(n=875)被随机分配到四个干预组(铁叶酸(标准护理)、多种微量营养素、蛋白质能量或蛋白质能量+多种微量营养素),在“登记”(平均妊娠年龄为 13.6 周,范围 8-20 周)时开始直至分娩。铁叶酸和多种微量营养素组以片剂形式给药,蛋白质能量组以脂质基营养补充剂形式给药。所有干预组每天的剂量都含有 60mg 铁和 400μg 叶酸。从 24 至 52 周龄,所有组的婴儿均被随机分配接受每日脂质基营养补充剂,有或没有额外的微量营养素。通过超声在婴儿年龄 1、8、24 和 52 周时评估胸腺大小,并计算与体积相关的胸腺指数。详细收集了婴儿生长、喂养状况和发病率的数据。
共有 724(82.7%)对母婴完成了 52 周龄的试验。在任何产后时间点,婴儿的胸腺大小与母亲补充组均无显著相关性。接受每日含额外微量营养素的 LNS 的婴儿在 52 周龄时的胸腺指数显著增大(相当于胸腺指数增加 8.0%[95%CI 2.89,13.4],P=0.002)。未观察到母亲和婴儿补充组之间存在相互作用。
在婴儿后期给予富含微量营养素的脂质基补充剂可增加胸腺大小,这是免疫功能的关键介质。改善边缘微量营养素状况人群的婴儿的微量营养素状况可能会改善免疫发育和生存。
ISRCTN 注册中心(controlled-trials.com)标识符:ISRCTN49285450。